Stratifying patients according to induction remission response showed that B-ALL achieved remission had cortactin gene expression with a median of 4.6 before treatment compared to 1.2 after treatment (P<0.001) and median HS1 gene expression was 19.7 before treatment compared to 6.6 after treatment (P<0.001). This evidence concerns the gene CTTN and acute lymphoblastic leukemia.